Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAT | P00750 | 2/20 | 0.44 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 13/20 | 0.38 |
| ▸ | BCAT1 | P54687 | 13/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16077836 | 0.78 | PLAT (0.47) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL12953361 | 0.72 | KDM4E (0.43) | PLATKDM4DBCAT1KDM4EALDH1A1 | |
| SCHEMBL31624313 | 0.71 | PLAT (0.49) | PLATKDM4EALDH1A1 | |
| SCHEMBL15659374 | 0.70 | KDM4E (0.43) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL15660032 | 0.70 | XDH (0.35) | PLATBCAT2BCAT1KDM4EALDH1A1 | |
| SCHEMBL16049130 | 0.69 | KDM5A (0.49) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL15660541 | 0.69 | XDH (0.42) | PLATKDM4D | |
| SCHEMBL15658303 | 0.69 | ABL1 (0.43) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL170616 | 0.68 | KDM4D (0.40) | PLATKDM4DKDM4EALDH1A1 | |
| SCHEMBL23500726 | 0.68 | KDM4D (0.52) | PLATKDM4DKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2022-06-30 | — | — | US | disclosed |
| WO-2020219963-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | UNIVERSITY OF HOUSTON SYSTEM (US) | 2020-10-29 | — | — | WO | disclosed |
| EP-2970307-B1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-03-11 | — | — | EP | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-10035801-B2 | Pyrazolo compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-31 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-03-03 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014139326-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10035801-B2 | Pyrazolo compounds and uses thereof | KDM5A, KDM5C, KDM5B | PLAT 4107/4885KDM4D 18/4885BCAT2 2043/4885 |
| US-20140275092-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM1B, DOT1L, EHMT1 | PLAT 3741/4885KDM4D 32/4885BCAT2 2586/4885 |
| US-20160060267-A1 | PYRAZOLO COMPOUNDS AND USES THEREOF | KDM5A, KDM5C, KDM5B | PLAT 4107/4885KDM4D 18/4885BCAT2 2043/4885 |
| US-20220202792-A1 | METHODS AND COMPOSITIONS FOR TREATING CHRONIC INFLAMMATORY INJURY, METAPLASIA, DYSPLASIA AND CANCERS OF EPITHELIAL TISSUES | FABP2, MUC1, FABP6 | PLAT 270/4885KDM4D 4516/4885BCAT2 4107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.